TD Cowen reiterates buy rating on Agios stock ahead of key trial data

TD Cowen reiterated its buy rating on Agios Pharmaceuticals (AGIO), citing confidence in mitapivat's potential to reduce vaso-occlusive crises in sickle cell disease, with Phase 3 trial data expected by year-end 2025 and a potential $4 billion sales opportunity. The firm views Agios as undervalued, trading at an enterprise value of $500 million, and anticipates significant upside (over 100%) upon positive trial results; Agios also has a September 7 PDUFA date for mitapivat in thalassemia, potentially adding $1 billion in global sales. Agios has also entered into a commercial and distribution agreement with Avanzanite Bioscience for Pyrukynd in Europe, Switzerland, and the United Kingdom.

Analysis

TD Cowen has reiterated its buy rating on Agios Pharmaceuticals (NASDAQ:AGIO), citing high conviction in its lead drug, mitapivat, ahead of pivotal clinical trial results. The firm anticipates mitapivat will demonstrate a significant benefit in reducing vaso-occlusive crises (VOCs) in the Phase 3 RISE-UP trial for sickle cell disease (SCD), with data expected by year-end 2025, potentially unlocking a $4 billion market opportunity. Agios, currently trading with an enterprise value of approximately $500 million and a market capitalization of $2.06 billion, is viewed as undervalued by TD Cowen and InvestingPro's Fair Value analysis, especially given the upcoming September 7 PDUFA date for mitapivat in thalassemia, an indication that could generate nearly $1 billion in global sales. Supporting this optimism, previous Phase 2 SCD data showed up to a 70% VOC reduction with mitapivat, and analogous PKR activator, Novo's etavopivat, demonstrated a ~46% reduction. TD Cowen projects that positive Phase 3 data could drive over 100% upside in AGIO's stock by the end of 2025, with some analyst targets reaching $71. Strategically, Agios has entered a commercial and distribution agreement with Avanzanite Bioscience to expand Pyrukynd (mitapivat) access in Europe. While H.C. Wainwright and Scotiabank adjusted price targets to $56 and $71 respectively (maintaining Buy/Outperform), Cantor Fitzgerald reiterated an Overweight rating, confident in thalassemia sales projections of $300-$500 million. The company also benefits from a "GREAT" financial health score, according to InvestingPro.

Key Decisions for Investors

• Investors should consider Agios Pharmaceuticals' current valuation in light of its significant upcoming catalysts, including the September 7 PDUFA date for mitapivat in thalassemia and the Phase 3 RISE-UP trial data for sickle cell disease expected by year-end 2025, which could unlock substantial market opportunities.
• Close monitoring of these key clinical and regulatory milestones is warranted, as positive outcomes could validate TD Cowen's projection of over 100% stock upside and affirm the drug's multi-billion dollar sales potential.
• While the strong analyst conviction, supportive early-stage data, and strategic European commercialization agreement for Pyrukynd are positive indicators, investors must weigh the potential for significant returns against the inherent risks associated with binary outcomes in biotechnology clinical trials and regulatory approvals.